The US FDA has declined to approve Summit Therapeutics’ BLA for ivonescimab in patients with locally advanced or metastatic NSCLC.
Following the 2026 US midterm elections, Democrats are putting healthcare affordability, drug pricing and insurance coverage at the centre of their agenda. Speaking at HLTH USA in Las Vegas, Senator ...
The main recipients of this fund will be European life sciences companies, though some across the US and other geographies will also benefit.
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme, a controversial expedited review framework established by ...
Omniose is developing a bioconjugate platform to create vaccines against multidrug resistant superbugs as anti-microbial resistance rises.
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s ...
Takeda has commercially launched Orzeyful (oveporexton) in the US as a prescription treatment for adult patients with narcolepsy type 1.
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
CRL has signed definitive agreements to acquire Frontage’s bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.
Emerging mechanisms and combinatorial approaches are redefining the obesity space as the outcome focus shifts away from weight loss alone.
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results